menu

QuintilesIMS Blog

Fresh ideas and insights from our experts around the globe

distribution
Brazilians flock to pharmacies: How healthcare companies can bolster sales by embracing this shifting shopper trend
Brad Smith
Recent advances in personalized medicine and genomic technologies have led to innovative developments in oncology research and practice. As we develop a better understanding of the biology of cancer we are able to develop drugs to target niche populations of patients with tumors that demonstrate unique molecular alterations. The ability to treat these sub-populations with targeted treatments often results in higher response rates among trial participants which enables the industry to drive these drugs to market faster giving patients access to these important treatments. This is exciting news for researchers, patients, physicians and payers, all of whom benefit from a precision medicine approach for cancer treatment. However, by narrowing the target population down to such specific...
Read More
CynthiaJackson
February 28 is Rare Disease Day – a day when we focus on the plight of the thousands of people who live with rare diseases. Paradoxically, the greatest proportion of the population suffering from rare diseases are children. There are approximately 7,000 rare diseases identified in the United States, and about 80 percent of these diseases are genetic – meaning people spend their entire lives dealing with the disease. As a result, it is estimated that half of all rare diseases affect children . It is interesting to note that although individual rare diseases are uncommon, collectively they affect more children and families than most people realize and my family is no exception. My 5-year old nephew suffers from Idiopathic Pulmonary Hypertension diagnosed when he was 4 months old. He...
Read More
Gavin Jones
In this post, I will examine outcomes evaluations and how they can help biopharma demonstrate value and outcomes at a local level in the UK. For biopharma, proving the value of a drug is key to its success in the local health economy. During the process of determining a drug’s effectiveness within a local heath economy it is important that all potential data sources are utilised when developing a case for funding with decision makers and a local outcomes assessment can be an important element of this case presentation. With this in mind, outcomes evaluations and outcomes audits are suitable methods for proving a drug’s value and measuring treatment effectiveness using observational data.  We have previously discussed outcomes audits in detail, however this approach looks at data...
Read More
Adrian McKemey
In this post, I will examine outcomes evaluations and how they can help biopharma demonstrate value and outcomes at a local level in the UK. For biopharma, proving the value of a drug is key to its success in the local health economy. During the process of determining a drug’s effectiveness within a local heath economy it is important that all potential data sources are utilised when developing a case for funding with decision makers and a local outcomes assessment can be an important element of this case presentation. With this in mind, outcomes evaluations and outcomes audits are suitable methods for proving a drug’s value and measuring treatment effectiveness using observational data.  We have previously discussed outcomes audits in detail, however this approach looks at data...
Read More
Retaining Value Learning and Future Insights throughout the Value Chain
Integration across multiple elements of the biopharma industry value chain should be a core aim for most service provider organizations who wish to differentiate their business and build a ‘higher barrier to entry’ service portfolio (as discussed here ). Of course while it is possible to articulate the value of doing this, most large biopharma organizations are just not set up to procure services this way, particularly in the late stage clinical and commercial environment, because of the decentralized local affiliate model and also because of silos within other therapeutic or functional groups. However, with the need to control healthcare system expenditure becoming ever more acute and consequently the need to show true ‘product value’ in terms of real world outcomes more critical...
Read More
Nathalie Horowicz-Mehler
In today’s value driven healthcare environment, the final hurdle for any drug to thrive is no longer regulatory approval — it is now payer support. Even if a drug receives marketing authorization, if payers won’t reimburse for the drug, than doctors won’t prescribe it and patients won’t use it. We’ve seen many examples over the years of good drugs with suboptimal access to patients because payers didn’t get behind them. But it doesn’t have to happen.  Early engagement strategies can help biopharma companies identify and dissipate the concerns payers may have about a new treatment option long before they come to market, thus improving the odds of their success. Payers want this kind of engagement, and the biopharma companies that incorporate interaction with them early in the...
Read More
Gavin Jones
To better understand local clinical and payer insight, biopharma need to engage with stakeholders early to see how they perceive current unmet needs, as well as perception of key clinical, policy and economic drivers. Insight can be collected from a variety of stakeholders – including patients, physicians, payers and policymakers; and can be collected via advisory boards, one-on-one interviews or secondary research. Objectives for biopharma in engaging pre-launch with the NHS Strict rules around governance will impact any pre-launch activity. Clause 3.3 of the PMCPA guidance outlines that engagement with NHS decision makers is allowed when there is a need for them to receive advanced information about new medicines that may significantly affect their future expenditure. Gaining an...
Read More
RickSax
At the heart of a quality clinical design process is the availability of good information. Without the ability to access multiple sources of data, as well as the proper tools for integrating, objectively analyzing and modeling such data, then applying it to design, biopharmaceutical companies will remain challenged to improve the success rate of drug candidates. One of the underlying tenets of “design thinking” is to integrate information to determine what is known, and more importantly, to determine the unknown (e.g., hypotheses, assumptions, risks). This allows the design effort to focus directly on addressing these unknowns, while minimizing the introduction of inadvertent bias.  For the most part, there are only two levers a company can pull to drive better outcomes:...
Read More
RickSax
At the heart of a quality clinical design process is the availability of good information. Without the ability to access multiple sources of data, as well as the proper tools for integrating, objectively analyzing and modeling such data, then applying it to design, biopharmaceutical companies will remain challenged to improve the success rate of drug candidates. One of the underlying tenets of “design thinking” is to integrate information to determine what is known, and more importantly, to determine the unknown (e.g., hypotheses, assumptions, risks). This allows the design effort to focus directly on addressing these unknowns, while minimizing the introduction of inadvertent bias.  For the most part, there are only two levers a company can pull to drive better outcomes: selection...
Read More
Helena Zhang
More and more regulators are demanding real-world outcomes data after medicinal product authorization. Even the most innovative clinical trials require outcome studies to further demonstrate the safety, effectiveness and risk/benefit evaluation of the treatment in diverse populations in China. However, our clinical trial models at present often lack the processes and resources to gather this data. This gap can only be closed if we as an industry more proactively pursue the collection of evidence-based data through observational studies as part of our broader trial initiatives. By investing time and resources into real world late phase (RWLP) studies, we can broaden the medical research horizon, stimulate evidence-based medicine, and strengthen partnership between the medical community...
Read More